Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

被引：58

作者：

Gower, Arjan ^{[1
]}

Wang, Yisong ^{[1
]}

Giaccone, Giuseppe ^{[1
]}

机构：

[1] Georgetown Univ, Washington, DC 20057 USA

来源：

JOURNAL OF MOLECULAR MEDICINE-JMM | 2014年 / 92卷 / 07期

关键词：

Non-small-cell lung cancer; Oncogenic drivers; TKIs; RTKs; Acquired resistance; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; MOLECULAR TESTING GUIDELINE; OF-AMERICAN-PATHOLOGISTS; EML4-ALK FUSION GENE; OPEN-LABEL; PHASE-III; ALK INHIBITOR; EGFR MUTATION; GEFITINIB RESISTANCE;

D O I：

10.1007/s00109-014-1165-y

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following molecular profiling has dramatically changed the way advanced adenocarcinoma is treated. However, tumor cells inevitably acquire resistance to such therapies, circumventing any sustained clinical benefit. As the genomic classification of lung cancer continues to evolve and as the mechanisms of acquired resistance to targeted therapies become elucidated and more improved target-specific drugs come into sight, the future will see more promising results from the clinic through the development of new therapeutic strategies to overcome, or prevent the development of, resistance for lung cancer patients.

引用

页码：697 / 707

页数：11

共 117 条

[71] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [J].

Pao, W ;

Miller, VA ;

Politi, KA ;

Riely, GJ ;

Somwar, R ;

Zakowski, MF ;

Kris, MG ;

Varmus, H .

PLOS MEDICINE, 2005, 2 (03) :225-235

[72] Chipping away at the lung cancer genome [J].

Pao, William ;

Hutchinson, Katherine E. .

NATURE MEDICINE, 2012, 18 (03) :349-351

[73] Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer [J].

Pao, William ;

Chmielecki, Juliann .

NATURE REVIEWS CANCER, 2010, 10 (11) :760-774

[74] Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer [J].

Rikova, Klarisa ;

Guo, Ailan ;

Zeng, Qingfu ;

Possemato, Anthony ;

Yu, Jian ;

Haack, Herbert ;

Nardone, Julie ;

Lee, Kimberly ;

Reeves, Cynthia ;

Li, Yu ;

Hu, Yerong ;

Tan, Zhiping ;

Stokes, Matthew ;

Sullivan, Laura ;

Mitchell, Jeffrey ;

Wetzel, Randy ;

MacNeill, Joan ;

Ren, Jian Min ;

Yuan, Jin ;

Bakalarski, Corey E. ;

Villen, Judit ;

Kornhauser, Jon M. ;

Smith, Bradley ;

Li, Daiqiang ;

Zhou, Xinmin ;

Gygi, Steven P. ;

Gu, Ting-Lei ;

Polakiewicz, Roberto D. ;

Rush, John ;

Comb, Michael J. .

CELL, 2007, 131 (06) :1190-1203

[75] Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J].

Rosell, Rafael ;

Carcereny, Enric ;

Gervais, Radj ;

Vergnenegre, Alain ;

Massuti, Bartomeu ;

Felip, Enriqueta ;

Palmero, Ramon ;

Garcia-Gomez, Ramon ;

Pallares, Cinta ;

Miguel Sanchez, Jose ;

Porta, Rut ;

Cobo, Manuel ;

Garrido, Pilar ;

Longo, Flavia ;

Moran, Teresa ;

Insa, Amelia ;

De Marinis, Filippo ;

Corre, Romain ;

Bover, Isabel ;

Illiano, Alfonso ;

Dansin, Eric ;

de Castro, Javier ;

Milella, Michele ;

Reguart, Noemi ;

Altavilla, Giuseppe ;

Jimenez, Ulpiano ;

Provencio, Mariano ;

Angel Moreno, Miguel ;

Terrasa, Josefa ;

Munoz-Langa, Jose ;

Valdivia, Javier ;

Isla, Dolores ;

Domine, Manuel ;

Molinier, Olivier ;

Mazieres, Julien ;

Baize, Nathalie ;

Garcia-Campelo, Rosario ;

Robinet, Gilles ;

Rodriguez-Abreu, Delvys ;

Lopez-Vivanco, Guillermo ;

Gebbia, Vittorio ;

Ferrera-Delgado, Lioba ;

Bombaron, Pierre ;

Bernabe, Reyes ;

Bearz, Alessandra ;

Artal, Angel ;

Cortesi, Enrico ;

Rolfo, Christian ;

Sanchez-Ronco, Maria ;

Drozdowskyj, Ana .

LANCET ONCOLOGY, 2012, 13 (03) :239-246

[76] Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer [J].

Ross, Helen J. ;

Blumenschein, George R., Jr. ;

Aisner, Joseph ;

Damjanov, Nevena ;

Dowlati, Afshin ;

Garst, Jennifer ;

Rigas, James R. ;

Smylie, Michael ;

Hassani, Habib ;

Allen, Kimberly E. ;

Leopold, Lance ;

Zaks, Tal Z. ;

Shepherd, Frances A. .

CLINICAL CANCER RESEARCH, 2010, 16 (06) :1938-1949

[77] Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer [J].

Rudin, Charles M. ;

Hong, Kelvin ;

Streit, Michael .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (05) :E41-E42

[78] MET As a Possible Target for Non-Small-Cell Lung Cancer [J].

Sadiq, Ahad A. ;

Salgia, Ravi .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1089-1096

[79] CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant [J].

Sakamoto, Hiroshi ;

Tsukaguchi, Toshiyuki ;

Hiroshima, Sayuri ;

Kodama, Tatsushi ;

Kobayashi, Takamitsu ;

Fukami, Takaaki A. ;

Oikawa, Nobuhiro ;

Tsukuda, Takuo ;

Ishii, Nobuya ;

Aoki, Yuko .

CANCER CELL, 2011, 19 (05) :679-690

[80] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

← 3 4 5 6 7 8 9 10 11 12 →